| Document |
Document Title |
|
WO/2022/168884A1 |
The present invention provides a novel cationic lipid having excellent encapsulation and delivery stability of nucleic acid medicines. Provided is a compound represented by formula (I) or a pharmacologically acceptable salt thereof. (In ...
|
|
WO/2022/166866A1 |
A class of macrocyclic compounds containing a dihydropyrazine and pyrazine structure, and, in particular, disclosed are a compound represented by formula (I) and a pharmaceutically acceptable salt thereof.
|
|
WO/2022/166762A1 |
The present invention relates to a Camptothecin compound having anti-tumor activity, a preparation method therefor, and an application thereof. Specifically, the present invention relates to a compound as shown below or a pharmaceuticall...
|
|
WO/2022/166799A1 |
Provided are a fused tricyclic cyclin-dependent kinase inhibitor, and a preparation method therefor and a pharmaceutical use thereof. In particular, the structure of the fused tricyclic cyclin-dependent kinase inhibitor is shown in formu...
|
|
WO/2022/167445A1 |
The present invention provides compounds of formula I, compositions thereof, and methods of using the same for the inhibition of GPR84, and the treatment of GPR84-mediated disorders.
|
|
WO/2022/169948A1 |
Described herein are novel PRMT5 inhibitors of Formula I and pharmaceutically acceptable salts thereof, as well as the pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity and m...
|
|
WO/2022/170268A1 |
The present invention provides a compound having the structure: [STRUCTURE}, wherein D,E,F,X1, X2 and R1-R14 are as defined herein; a pharmaceutical composition comprising said compound and a pharmaceutically acceptable carrier; and a me...
|
|
WO/2022/169997A1 |
Various lactam compound that binds Cbl-B, many of which are selective for Cbl-B over C-Cbl, and methods of making and using the same. Representative lactam compounds include molecules falling within the following formulae:
|
|
WO/2022/106469A3 |
The present invention provides compounds of formula (I), for the treatment of an infection in warm-blooded animal caused by endoparasites, more preferably a helminthic infection, even more preferably a heartworm infection. Exemplary comp...
|
|
WO/2022/166845A1 |
The present invention relates to a compound of formula (I) capable of inhibiting plasmin activity and having blood coagulation and hemostasis activity, and a pharmaceutically acceptable salt, hydrate, isomer, prodrug, and mixture thereof...
|
|
WO/2022/167457A1 |
The present invention provides compounds of formula (I), compositions thereof, and methods of using the same for the inhibition of GPR84, and the treatment of GPR84-mediated disorders.
|
|
WO/2022/163446A1 |
The present invention addresses the problem of providing a new compound that binds specifically to intracellular and/or extracellular vesicles, a cellular vesicle stain, and a method for fluorescent staining of cellular vesicles.　The p...
|
|
WO/2022/162471A1 |
Disclosed are compounds, compositions, and methods useful for treating neuronal and mitochondrial diseases.
|
|
WO/2022/164789A1 |
The present application relates to compounds of Formula (I), as defined herein, and pharmaceutically acceptable salts thereof. The present application also describes pharmaceutical composition comprising a compound of Formula (I), and ph...
|
|
WO/2022/161479A1 |
The present invention provides a toxin molecule suitable for an antibody-drug conjugate. In particular, the present invention provides a compound represented by formula (I) below or a pharmaceutically acceptable salt or hydrate thereof. ...
|
|
WO/2022/161443A1 |
The present application relates to a pyrimidopyran compound, and specifically discloses a compound as represented by formula (III), and a pharmaceutically acceptable salt thereof.
|
|
WO/2022/161480A1 |
The present invention relates to a substituted bicyclo-aromatic heterocyclic amine inhibitor, a preparation method therefor, and the use thereof. Specifically, a compound of the present invention has a structure as represented by formula...
|
|
WO/2022/159980A1 |
Disclosed herein are compounds (e.g., pyrrole compounds, carboxy pyrroles, etc.), including pharmaceutical compositions that include one or more of such compounds (e.g., carboxy pyrroles). Also disclosed are methods of making carboxy pyr...
|
|
WO/2022/155860A1 |
The disclosure provides at compounds of Formula I, compositions comprising the same, and methods of using the same, including use in treating diseases, disorders of conditions mediated by the signaling of formyl peptide receptor 1 (FPR1).
|
|
WO/2022/157599A1 |
A novel organic compound is provided, specifically, a novel organic compound effective in heightening element characteristics is provided. This organic compound is represented by general formula (G1). In general formula (G1), at least on...
|
|
WO/2022/157271A1 |
The present invention relates to compounds of formula (I), which are modulators of sortilin activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment...
|
|
WO/2022/156765A1 |
Disclosed is a pyrazolopyrazine-linked tricyclic compound represented by formula (I) or a pharmaceutically acceptable salt thereof. The compound has inhibitory activity on protein tyrosine phosphatase SHP2 and can be used to treat diseas...
|
|
WO/2022/156761A1 |
Provides compounds represented by Formula(I): wherein R 3, R 8c, R 8d, A, A 1, A 2, A 3, A 4, E, E 1, L, Q, Z, and (II) are as defined in the specification, and the pharmaceutically acceptable salts and solvates thereof. Compounds of For...
|
|
WO/2022/159981A1 |
Disclosed herein are triazine compounds (e.g., triazines and pyrazole triazines) and methods of treating diseases and/or conditions (e.g., inflammation) with the triazine compounds disclosed herein. In several embodiments, the disclosed ...
|
|
WO/2022/153268A1 |
This invention relates to pharmaceutically acceptable tryptamine analogues and salts thereof. In particular, though not exclusively, the invention relates to formulations and uses of the same as a medicament.
|
|
WO/2022/152705A1 |
Compounds of Formula (I) wherein R1, R3, R11, R12, X, Y1, Y2, Y3, Y4 and formula (II) are as defined in the description. Medicaments.
|
|
WO/2022/150917A1 |
The invention relates to crystalline forms of Alpha-1062 gluconate (scheme I: (I)). In one aspect, the invention relates to a crystalline solid form of Alpha-1062 gluconate (Form A), wherein said crystalline form has prominent peaks at 3...
|
|
WO/2022/152233A1 |
Provided are compounds of Formula (I) or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof useful as G12C inhibitors, and a pharmaceutical composition comprising the same.
|
|
WO/2022/149856A1 |
The present invention provides a compound, having a specific chemical structure, having a Bruton's tyrosine kinase (BTK)-inhibiting activity, or a pharmaceutically acceptable salt thereof. The present invention provides a composition com...
|
|
WO/2022/149757A1 |
The present invention relates to a novel heterocyclic compound and an organic light-emitting device comprising same. The heterocyclic compound, according to the present invention, is a polycyclic heterocyclic compound which has a condens...
|
|
WO/2022/148421A1 |
Provided are bridged compounds as well as their compositions and methods of use. The compounds disclosed herein inhibit KRAS G12D activity and are useful in the treatment of various diseases including cancer.
|
|
WO/2022/150345A1 |
The present disclosure describes, in part, methods for diagnosing and/or treating autoimmune diseases using a compound capable of inhibiting eHsp90.
|
|
WO/2022/144423A1 |
The invention relates to a chemical compound of general formula (I), to an optoelectronic component containing such a compound, and to the use of such a compound in an optoelectronic component.
|
|
WO/2022/143489A1 |
A tricyclic compound having the structure represented by general formula (I), a pharmaceutical composition thereof, a preparation method therefor and the use thereof in the prevention and treatment of a variety of diseases caused by toxi...
|
|
WO/2022/143533A1 |
Disclosed are a quinazoline derivative of formula (I), a pharmaceutical composition containing the derivative and the use thereof in medicine, in particular the use as an SOS1 inhibitor and the use in the preparation of a medicament for ...
|
|
WO/2022/139167A1 |
The present specification relates to a heterocyclic compound represented by chemical formula 1, an organic light-emitting device comprising same, a manufacturing method therefor, and a composition for an organic layer.
|
|
WO/2022/140456A1 |
This disclosure is in the field of medicinal chemistry, and relates to a new class of small-molecules having the Formula I, or a pharmaceutically acceptable salt or solvate thereof, or an enantiomer, a mixture of enantiomers, a mixture o...
|
|
WO/2022/137085A1 |
The present disclosure relates to a compound of Formula (I): (I), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, wherein R1 through R8 are as defined herein, and methods of making and using th...
|
|
WO/2022/138944A1 |
The present disclosure provides a pharmaceutical composition for treating and/or preventing SWI/SNF complex-dysfunction cancer. More specifically, according to the present disclosure, a compound represented by formulae (1) to (23) (the f...
|
|
WO/2022/133816A1 |
The present invention provides a porphyrin compound and a preparation method therefor and use thereof, and a pharmaceutical composition using the porphyrin compound as an active ingredient. The porphyrin compound has a novel and adjustab...
|
|
WO/2022/134074A1 |
An organic electroluminescent device, a display panel, a display device and a light-emitting device are provided, belonging to the technical field of display. The organic electroluminescent device comprises an anode, an electron blocking...
|
|
WO/2022/140169A1 |
Invented are compounds of formula I and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are DGAT2 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising c...
|
|
WO/2022/138987A1 |
The present invention provides a compound exhibiting a coronavirus 3CL protease inhibitory effect and pharmaceutically acceptable salts thereof, and a pharmaceutical composition containing the same. Further provided are crystals that are...
|
|
WO/2021/122415A9 |
The present invention covers furoindazole compounds of general formula (I): in which (I) are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions ...
|
|
WO/2022/135546A1 |
The present invention relates to a spirocyclic compound, represented by formula (I), as a KRAS-G12C inhibitor, which can be used in the preparation of a drug for treating KRAS G12C-mediated tumors.
|
|
WO/2022/138791A1 |
The purpose of the present invention is to provide a medicine for the prevention and/or treatment of a disease caused by activation of an EP2 receptor, said medicine containing, as an active ingredient, a compound having an antagonistic ...
|
|
WO/2022/139180A1 |
The present invention provides a heterocyclic compound represented by chemical formula 1 and an organic light-emitting device comprising same.
|
|
WO/2022/139228A1 |
The present specification relates to a heterocyclic compound represented by chemical formula 1, an organic light-emitting device comprising same, a manufacturing method therefor, and a composition for an organic material layer.
|
|
WO/2022/139360A1 |
The present invention relates to a novel compound with excellent electron transport, light emission, and heat stability, and to an organic electroluminescent device that includes the compound in at least one organic material layer to hav...
|
|
WO/2022/140504A1 |
Provided herein are antibody-drug conjugates, for example, a compound of Formula (I), and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms o...
|
